Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Consensus Recommendation of “Buy” by Brokerages

Aquestive Therapeutics, Inc. (NASDAQ:AQST) has earned a consensus rating of “Buy” from the seven brokerages that are currently covering the company, MarketBeat reports. Six analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $11.00.

Several research firms have recently issued reports on AQST. JMP Securities restated a “market outperform” rating and set a $9.00 price objective on shares of Aquestive Therapeutics in a report on Tuesday, October 8th. Cantor Fitzgerald began coverage on shares of Aquestive Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $17.00 price target for the company. Leerink Partners raised their target price on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Aquestive Therapeutics in a report on Friday, December 20th.

Hedge Funds Weigh In On Aquestive Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Victory Capital Management Inc. purchased a new position in Aquestive Therapeutics in the second quarter worth $27,000. nVerses Capital LLC purchased a new stake in shares of Aquestive Therapeutics in the third quarter valued at $28,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Aquestive Therapeutics in the second quarter worth approximately $76,000. Harvey Capital Management Inc. purchased a new position in shares of Aquestive Therapeutics in the 3rd quarter worth $88,000. Finally, Intech Investment Management LLC acquired a new stake in Aquestive Therapeutics during the 3rd quarter worth approximately $90,000. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Price Performance

NASDAQ AQST opened at $3.10 on Wednesday. The stock has a market capitalization of $282.66 million, a PE ratio of -6.89 and a beta of 2.71. The business has a 50 day simple moving average of $3.97 and a two-hundred day simple moving average of $4.19. Aquestive Therapeutics has a 1-year low of $2.24 and a 1-year high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last released its earnings results on Monday, November 4th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The firm had revenue of $13.54 million during the quarter, compared to analyst estimates of $12.69 million. During the same period last year, the business posted ($0.03) EPS. On average, analysts anticipate that Aquestive Therapeutics will post -0.46 EPS for the current fiscal year.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.